Astellas Pharma logo

Astellas Pharma(OTC) ALPMF

Market Cap$27.43BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-43%
5 Year+14%
1 Year+47%
1 Month-2%
$15.30
-0.33%
-0.05Today
Astellas Pharma last closing stock price
MetricPriceDate
Last closeUSD 15.302026-10-12
Astellas Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.33%USD 15.252026-10-05
1 month-1.89%USD 15.592026-09-11
3 month+21.01%USD 12.642026-07-14
Year to date+19.89%USD 12.762025-12-30
1 year+47.19%USD 10.392025-10-10
3 year+32.11%USD 11.582023-10-13
5 year+14.09%USD 13.412021-10-11
Since inception-42.79%USD 26.742003-07-15

Astellas Pharma Financials at a Glance

Market Cap

$27.43BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥2.28T

Net Income (TTM)

¥365.30B

EPS (TTM)

$1.31

P/E Ratio

11.63

Dividend

$0.50

Beta (Volatility)

0.03 (Low)

Price

$15.30

Volume

677

Open

$13.62

Previous Close

$15.30

Daily Range

$13.62 - $15.30

52-Week Range

$9.85 - $17.85

Estimated Earnings Date

Nov 4, 2026

ALPMF News

GettyImages-1146913659

A $20 Billion Sweet Spot in Biotech

David HaenDec 28, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Astellas Pharma

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, focusing on the development, manufacturing, distribution, and commercialization of medicinal products. The company is known for its diverse portfolio, which includes innovative therapies for various medical conditions.

Products and Services
  • XTANDI for prostate cancer treatment
  • XOSPATA for acute myeloid leukemia
  • PADCEV for urothelial cancer
Growth Outlook
  • Recent quarterly revenue reached JPY 636.3 billion, a significant increase
  • Strong demand for key products supports future growth potential
  • Strategic alliances enhance research and development capabilities
Financial Highlights
  • Trailing twelve months revenue of JPY 2.4 trillion
  • Net income margin stands at 16.04%, indicating profitability
  • Dividend yield of 3.30% reflects commitment to shareholder returns
Astellas Pharma Inc. has established itself as a key player in the pharmaceutical industry, with a strong focus on innovative therapies. The company's recent financial performance demonstrates robust revenue growth and profitability, supported by a diverse product portfolio. Strategic partnerships and collaborations further enhance its research capabilities, positioning Astellas for continued success in the evolving healthcare landscape. The commitment to shareholder returns is evident through a competitive dividend yield, making it an attractive option for potential investors.
AI Generated • Sep 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14,099

CEO

Naoki Okamura

Website

www.astellas.com

Headquarters

Tokyo, TY 103-8411, JP

ALPMF Financials

Key Financial Metrics (TTM)

Gross Margin

74.71%

Operating Margin

21.81%

Net Income Margin

16.04%

Return on Equity

20.41%

Return on Capital

17.51%

Return on Assets

9.88%

Earnings Yield

8.60%

Dividend Yield

3.27%

Payout Ratio

38.30%

Stock Overview

Market Cap

$27.43BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.79B

Volume

677

Avg. Volume

8.19K

Financials (TTM)

Gross Profit

¥1.70T

Operating Income

¥496.73B

EBITDA

¥705.06B

Operating Cash Flow

¥602.03B

Capital Expenditure

-¥57.75B

Free Cash Flow

¥544.28B

Cash & ST Invst.

¥242.93B

Total Debt

¥585.60B

Astellas Pharma Performance Analysis

Astellas Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 11,210,593,310-2.8%
20242024-03-31JPY 11,104,729,504-0.9%
20252025-03-31JPY 12,543,905,53613.0%
20262026-03-31JPY 14,196,133,79713.2%
Astellas Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-305.1%
Q32025-12-317.5%
Q42026-03-31-5.3%
Q12026-06-3017.5%
Astellas Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.40-33.1%
20242024-03-31JPY 0.07-83.6%
20252025-03-31JPY 0.19182.3%
20262026-03-31JPY 1.08481.3%
Astellas Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3017.3%
Q32025-12-3125.1%
Q42026-03-31-57.1%
Q12026-06-30230.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥636.28B

+25.8%

Gross Profit

¥479.05B

+16.6%

Gross Margin

75.29%

N/A

Market Cap

$27.43BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.95M

N/A

Employees

14,099

N/A

Net Income

¥140.65B

+105.6%

EBITDA

¥233.93B

+54.1%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥242.93B

+12.8%

Total Debt

¥585.60B

-34.2%

Accounts Receivable

¥838.69B

+25.4%

Inventory

¥335.44B

+9.7%

Long Term Debt

¥317.69B

-43.1%

Short Term Debt

¥267.92B

-19.2%

Return on Assets

9.88%

N/A

Return on Invested Capital

20.18%

N/A

Free Cash Flow

¥74.47B

+77.2%

Operating Cash Flow

¥86.99B

+58.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,799.81-0.00%
^DJIDJI
$51,815.75+0.00%
^IXICNASDAQ
$27,233.87-0.00%
BTCBitcoin
$82,442.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.67-0.89%
INTCIntel
$101.35-3.20%
NOKNokia
$9.90-4.44%
NVDANvidia
$226.32-1.29%

Questions About ALPMF

What is the current price of Astellas Pharma?

Astellas Pharma is trading at $15.30 per share.

What is the 52-week range for Astellas Pharma?

Over the past 52 weeks, Astellas Pharma has traded between $9.85 and $17.85.

How much debt does Astellas Pharma have?

As of the most recent reporting period, Astellas Pharma reported total debt of ¥3.63B.

How much cash does Astellas Pharma have on hand?

Astellas Pharma reported ¥1.51B in cash and cash equivalents in its most recent financial results.

What is Astellas Pharma’s dividend yield?

Astellas Pharma currently has a dividend yield of 3.27%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services